Cartesian Therapeutics (RNAC) Free Cash Flow (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Free Cash Flow for 12 consecutive years, with -$22.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 8.36% year-over-year to -$22.2 million; the TTM figure through Mar 2026 stood at -$77.4 million (down 135.99% YoY), while the FY2025 annual figure was -$79.4 million, down 223.78% from the prior year.
• Free Cash Flow improved to -$22.2 million in Q1 2026 per RNAC's latest filing, from -$23.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $15.5 million in Q3 2024 and bottomed at -$24.2 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$12.4 million across 5 years, with a median of -$12.9 million in 2022.
• Annual changes were most pronounced in 2023 — Free Cash Flow sank 303.89% — and 2024, when it jumped 267.76%.
• Cartesian Therapeutics' Free Cash Flow stood at -$12.9 million in 2022, then tumbled by 80.93% to -$23.3 million in 2023, then surged by 68.06% to -$7.5 million in 2024, then tumbled by 209.17% to -$23.1 million in 2025, then gained by 3.87% to -$22.2 million in 2026.
• Business Quant data shows RNAC's Free Cash Flow at -$22.2 million in Q1 2026, -$23.1 million in Q4 2025, and -$15.0 million in Q3 2025.